CIA
IOVA icon

Cape Investment Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

Cape Investment Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-168
Closed -$1.35K – 973
2024
Q2 		$1.35K Hold
168
– – ﹤0.01% 820
2024
Q1 		$2.49K Hold
168
– – ﹤0.01% 742
2023
Q4 		$1.37K Hold
168
– – ﹤0.01% 981
2023
Q3 		$764 Hold
168
– – ﹤0.01% 852
2023
Q2 		$1.18K Hold
168
– – ﹤0.01% 818
2023
Q1 		$1.03K Buy
+168
New +$1.16K ﹤0.01% 873

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Cape Investment Advisory's IOVA Position: Q3 2024 in Review

Cape Investment Advisory sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 168 shares — an estimated $1.35K sold.

Cape Investment Advisory first reported a position in IOVA in Q1 2023 and held it in 6 quarters. The position peaked at $2.49K in Q1 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Cape Investment Advisory reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Cape Investment Advisory sold 168 Iovance Biotherapeutics shares in Q3 2024, an estimated $1.35K.
  • Cape Investment Advisory first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 6 quarters.
  • Cape Investment Advisory's Iovance Biotherapeutics position peaked at $2.49K in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Cape Investment Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.